Detection of myo-inositol tris pyrophosphate (ITPP) in equine following an administration of ITPP

Drug Testing and Analysis

Volumn 6, Issue 3, 2014, Pages 268-276

  Lam, Geoffrey ^a   Zhao, Sarah ^a   Sandhu, Jasmeet ^a   Yi, Rong ^a   Loganathan, Devan ^a   Morrissey, Barbara ^a  

^a Maxxam Analytics Inc   (Canada)

Author keywords

Equine; HILIC; HPLC MS MS; Intravenous administration; ITPP; Plasma; Urine

Indexed keywords

ALCOHOLS; CELLS; CYTOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; POLYOLS; SUGARS;

EQUINE; HILIC; HPLC-MS-MS; INOSITOL TRIS PYROPHOSPHATE; INTRAVENOUS ADMINISTRATION; MYO-INOSITOL; PEAK CONCENTRATIONS; PLASMA SAMPLES; RED BLOOD CELL; URINE;

BLOOD;

INOSITOL PHOSPHATE; MYOINOSITOL TRIS PYROPHOSPHATE; PERFORMANCE ENHANCING SUBSTANCE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CHROMATOGRAPH; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG SCREENING; DRUG STABILITY; DRUG URINE LEVEL; EQUIDAE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; MARE; MEASUREMENT ACCURACY; NONHUMAN; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; URINALYSIS;

EQUINE; HILIC; HPLC-MS-MS; INTRAVENOUS ADMINISTRATION; ITPP; PLASMA; URINE;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HORSES; INOSITOL PHOSPHATES; LIMIT OF DETECTION; SUBSTANCE ABUSE DETECTION; TANDEM MASS SPECTROMETRY;

EID: 84896401586     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1473     Document Type: Article

References (19)

1. R. Benesch, R.E. Benesch. Intracellular organic phosphates as regulators of oxygen release by haemoglobin. Nature 1969, 221, 618.
2. R. Benesch, R.E. Benesch. The effect of organic phosphates from the human erythrocyte on the allosteric properties of haemoglobin. Biochem. Biophys. Res. Commun. 1967, 26, 162.
3. A. Arnone, M.F. Perutz. Structure of inositol hexaphosphate-human deoxyhaemoglobin complex. Nature 1974, 249, 3.
4. B. Teisseire, C. Ropars, M.O. Vallez, R.A. Herigault, C. Nicolau. Physiological effects of high-P50 erythrocyte transfusion on piglets. J. Appl. Physiol. 1985, 58, 1810.
5. W.N. Poillon, M.D. Robinson, B.C. Kim. Deoxygnated sickle hemoglobin. Modulation of its solubility by 2, 3-diphosphoglycerate and other allosteric polyanions. J. Biol. Chem. 1985, 260, 13897.
6. U. Bruggemann, E.C. Roux, J. Hanning, C. Nicolau. Low-oxygen-affinity red cells produced in a large-volume, continuous flow electroporation system. Transfusison 1995, 35, 478.
7. R.S. Franco, M. Weiner, K. Wagner, O.J. Martelo. Incorporation of inositol hexaphosphate into red blood cells mediated by dimethyl sulfoxide. Life Sci. 1983, 32, 2763.
8. K.C. Fylaktakidou, J.-M. Lehn, R. Greferath, C. Nicolau. Inositol tripyrophosphate: A new membrane permeant allosteric effector of haemoglobin. Bioorg. Med. Chem. Lett. 2005, 15, 1605.
9. C. Kieda, R. Grefereth, C. Crola da Silva, K.C. Fylaktakidou, J.-M. Lehn, C. Nicolau. Suppression of hypoxia-iduced HIF-1α and of angiogenesis in endothelial celles by myo-inositol trispyrophosphate-treated erythrocytes. P. Natl Acad. Sci. USA 2006, 103, 15576.
10. M. Aprahamian, G. Bour, C.Y. Akladios, K. Fylaktakidou, R. Greferath, L. Soler, J. Marescaux, J.-M. Egly, J.-M. Lehn, C. Nicolau. Myo-inositol trispyrophosphate treatment leads to HIF-1α suppression and eradication of early hepatoma tumors in rats. Chem. Bio. Chem. 2011, 12, 777.
11. A. Biolo, R. Grefereth, D.A. Siwik, F. Qin, E. Valsky, K.C. Fylaktakidou, S. Pothukanuri, C.D. Duarte, R.P. Schwarz, J.-M. Lehn, C. Nicolau, W.S. Colluci. Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. P. Natl Acad. Sci. USA 2009, 106, 1926.
12. A.E. Koumbis, C.D. Duarte, C. Nicolau, J.-M. Lehn. Tetrakisphosphates and bispyrophospahtes of myo-inositol derivatives as allosteric effectors of human hemoglobin: Synthesis. Molecular recognition and oxygen release. Chem. Med. Chem. 2011, 6, 169.
13. Phase 1 clinical trial of OXY111A initiated. News-Medical Net. Available at: http://www.news-medical.net/news/20100524/Phase-1-clinical-trial-of-OXY111A-initiated.aspx [1 April 2012].
14. US Cycling Athlete Accepts Sanction For Anti-Doping Rule Violation. United States Anti-Doping Agency. Available at: http://www.usada.org/sanction-brandt-sorenson-1-13-2012 [24 August 2012].
15. Experimental drugs draw attention for performance enhancement capabilities. Thoroughbred times. Available at: http://www.thoroughbredtimes.com/horse-health/news-story.aspx?value=Experimental-drug-draws-attention-for-performance-enhancement-capabilities&xml:id=793804&type=hhnews [30 March 2012].
16. Horsetalk.co.nz. New horse performance enhancing drug under spotlight. Available at: http://www.horsetalk.co.nz/news/2011/10/194.shtml [30 March 2012].
17. A.S.Y. Wong, E.N.M. Ho, T.S.M. Wan. Detection of myo-inositol trispyrophosphate in equine urine and plasma by hydrophilic interaction chromatography-tandem mass spectrometry. Drug Test. Analysis 2012, 4(5), 355.
18. F.F. Hsu, J. Turk, M.L. Gross. Structural distinction among inositol phosphate isomers using high-energy and low-energy collisional-activated dissociation tandem mass spectrometry with electrospray ionization. J. Mass Spectrom. 2003, 38, 447.
19. Method Development Guide for Hypercarb Columns. Thermo Scientific Technical Guide. Available at: http://www.thermoscientific.com/ecomm/servlet/newsdetail?storeId=11152&contentId=52076&ca=hypercarb [18 October 2012]